Search

Your search keyword '"Mazumdar M"' showing total 35 results
Start Over Author "Mazumdar M" Publisher american society of clinical oncology (asco)
35 results on '"Mazumdar M"'

12. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB

Author

Bajorin, D. F., primary, Nichols, C. R., additional, Margolin, K. A., additional, Bacik, J., additional, Richardson, P. G., additional, Vogelzang, N. J., additional, Einhorn, L., additional, Mazumdar, M., additional, Bosl, G. J., additional, and Motzer, R. J., additional

Published
2006
Full Text
View/download PDF

35. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer

Author

Russell B. McBride, Martin F. Casey, Madhu Mazumdar, William Oh, Kristian D. Stensland, Che-Kai Tsao, John P. Sfakianos, Erin Moshier, Paolo Boffetta, Matthew D. Galsky, Juan P. Wisnivesky, Galsky, M.D., Stensland, K.D., Moshier, E., Sfakianos, J.P., McBride, R.B., Tsao, C.-K., Casey, M., Boffetta, P., Oh, W.K., Mazumdar, M., and Wisnivesky, J.P.

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, 030232 urology & nephrology, Cystectomy, law.invention, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Humans, Survival analysis, Aged, Aged, 80 and over, Carcinoma, Transitional Cell, Chemotherapy, Bladder cancer, business.industry, Middle Aged, medicine.disease, Survival Analysis, Urinary Bladder Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Propensity score matching, Female, Observational study, business, Adjuvant
Abstract

Purpose Given that randomized trials exploring adjuvant chemotherapy for bladder cancer have been underpowered and/or terminated prematurely, yielding inconsistent results and creating an evidence gap, we sought to compare the effectiveness of cystectomy versus cystectomy plus adjuvant chemotherapy in real-world patients. Patients and Methods We conducted an observational study to compare the effectiveness of adjuvant chemotherapy versus observation postcystectomy in patients with pathologic T3-4 and/or pathologic node-positive bladder cancer using the National Cancer Data Base. We compared overall survival using propensity score (–adjusted, –stratified, –weighted, and –matched) analyses based on patient-, facility-, and tumor-level characteristics. A sensitivity analysis was performed to examine the impact of performance status. Results A total of 5,653 patients met study inclusion criteria; 23% received adjuvant chemotherapy postcystectomy. Chemotherapy-treated patients were younger and more likely to have private insurance, live in areas with a higher median income and higher percentage of high school–educated residents, and have lymph node involvement and positive surgical margins (P < .05 for all comparisons). Stratified analyses adjusted for propensity score demonstrated an improvement in overall survival with adjuvant chemotherapy (hazard ratio, 0.70; 95% CI, 0.64 to 0.76), and similar results were achieved with propensity score matching and weighting. The association between adjuvant chemotherapy and improved survival was consistent in subset analyses and was robust to the effects of poor performance status. Conclusion In this observational study, adjuvant chemotherapy was associated with improved survival in patients with locally advanced bladder cancer. Although neoadjuvant chemotherapy remains the preferred approach based on level I evidence, these data lend further support for the use of adjuvant chemotherapy in patients with locally advanced bladder cancer postcystectomy who did not receive chemotherapy preoperatively.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results